Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2414352 | 0.89 | HIF1A (0.40) | HIF1AKDM1AMAOAMAOBKCNH3 | |
| Iodide SCHEMBL13280558 | 0.79 | HIF1A (0.48) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL1969660 | 0.76 | HIF1A (0.44) | HIF1AKDM1AMAOAMAOBALDH1A1 | |
| Bromide SCHEMBL129506 | 0.75 | HIF1A (0.48) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL1968748 | 0.72 | ALDH1A1 (0.35) | HIF1AALDH1A1TSHR | |
| Bromide SCHEMBL6428595 | 0.72 | HIF1A (0.44) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL8182047 | 0.71 | HIF1A (0.40) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL8182049 | 0.71 | HIF1A (0.40) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL9822359 | 0.71 | ALDH1A1 (0.39) | HIF1AALDH1A1TSHR | |
| SCHEMBL5269898 | 0.71 | GBA1 (0.50) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2236498-A1 | PHENYL ACETAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | HIF1A 2722/4885KDM1A 1950/4885MAOA 1299/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | HIF1A 2150/4885KDM1A 2866/4885MAOA 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.